Neurogene Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Neurogene Inc. (NGNE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 3.30% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2019-03-07
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2018 was 3.30%, a 50.00% increase from fiscal 2017.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2017 was 2.20%, a 22.22% increase from fiscal 2016.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2016 was 1.80%, a 10.00% decline from fiscal 2015.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2015 was 2.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2018-12-31 | 3.30% 10-K · filed 2019-03-07 |
| 2017-12-31 | 2.20% 10-K · filed 2019-03-07 |
| 2016-12-31 | 1.80% 10-K · filed 2019-03-07 |
| 2015-12-31 | 2.00% 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |